You are here

Article Text

Article menu
Download PDFPDF
Rare disease
CASE REPORT
Squamous cell carcinoma arising in hypertrophic lichen planus
  1. Caroline Cecile Pauline Haenen1,
  2. Aletta Atje Jacoba Buurma2,
  3. Roel Erik Genders1,3,
  4. Koen D Quint1,3
  1. 1Department of Dermatology, LUMC, Leiden, The Netherlands
  2. 2Department of Pathology, LUMC, Leiden, The Netherlands
  3. 3Department of Dermatology, Roosevelt Clinics, Leiden, The Netherlands
  1. Correspondence to Dr Koen D Quint, k.d.quint{at}lumc.nl

Summary

Hypertrophic lichen planus (HLP) is a chronic T-cell-mediated inflammatory disease characterised by pruritic hypertrophic or verrucous plaques on the lower limbs. We report a case of an 87-year-old woman with a 12-year history of HLP on both lower legs presenting with malignant transformation of one lesion into a squamous cell carcinoma (SCC). Malignancy developing in cutaneous lichen planus is rare, with less than 50 cases reported in the literature. This case highlights the need to be aware of suspicious changes in long-standing HLP to allow early detection of a developing SCC.

  • dermatology
  • oncology
  • skin cancer

https://doi.org/10.1136/bcr-2017-224044

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors CCPH: first author of article, analysis and interpretation of data. AAJB: analysis of histology, co-author, critical revision of the work, final approval of the version to be published. REG: co-author, critical revision of the work, final approval of the version to be published. KDQ: co-author, critical revision of the work, final approval of the version to be published.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.